Current Developments in Pharmacogenomics of Multiple Sclerosis

被引：5
|
作者：
Carlson, Rebecca J. [1 ,2 ]
Doucette, J. Ronald [2 ,3 ,4 ]
Nazarali, Adil J. [1 ,4 ,5 ]
机构：
[1] Univ Saskatchewan, Coll Pharm & Nutr, Mol Cell Biol Lab, Saskatoon, SK S7N 5C9, Canada
[2] Univ Saskatchewan, Neurosci Res Grp, Saskatoon, SK S7N 5C9, Canada
[3] Univ Saskatchewan, Dept Anat & Cell Biol, Coll Med, Saskatoon, SK S7N 5C9, Canada
[4] City Hosp, Cameco Multiple Sclerosis Neurosci Res Ctr, Saskatoon, SK, Canada
[5] Univ Saskatchewan, Neurosci Res Grp, Saskatoon, SK S7N 5E2, Canada
来源：
CELLULAR AND MOLECULAR NEUROBIOLOGY | 2014年 / 34卷 / 08期
基金：
加拿大健康研究院;
关键词：
Pharmacogenomics; Multiple sclerosis; Interferon-beta; Glatiramer acetate; SNPs; Genome-wide association studies; INTERFERON-BETA THERAPY; GLATIRAMER ACETATE; GENE; SUSCEPTIBILITY; POLYMORPHISMS; MARKERS;
D O I：
10.1007/s10571-014-0095-0
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Pharmacogenomics has a significant potential to impact how we treat diseases. It involves targeting genetically identifiable populations with therapeutic interventions that promises to yield immediate positive health outcomes with lower or no side effects. The 'trial and error' method of treatment will no longer be necessary with the successful implementation of personalized medicine. The following is an overview of some new developments in pharmacogenomics of multiple sclerosis, and how it has the potential to improve future treatment.
引用
收藏
页码：1081 / 1085
页数：5
相关论文
共 50 条
  • [41] Current Disease-Modifying Treatment of Multiple Sclerosis
    Derwenskus, Joy
    MOUNT SINAI JOURNAL OF MEDICINE, 2011, 78 (02): : 161 - 175
  • [42] Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs
    Milo, Ron
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (05) : 659 - 673
  • [43] Management of multiple sclerosis: current trials and future options
    Noseworthy, JH
    CURRENT OPINION IN NEUROLOGY, 2003, 16 (03) : 289 - 297
  • [44] IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments
    Luchtman, Dirk W.
    Ellwardt, Erik
    Larochelle, Catherine
    Zipp, Frauke
    CYTOKINE & GROWTH FACTOR REVIEWS, 2014, 25 (04) : 403 - 413
  • [45] Headache in Multiple Sclerosis
    Putzki, Norman
    Katsarava, Zaza
    CURRENT PAIN AND HEADACHE REPORTS, 2010, 14 (04) : 316 - 320
  • [46] Headache in Multiple Sclerosis
    Norman Putzki
    Zaza Katsarava
    Current Pain and Headache Reports, 2010, 14 : 316 - 320
  • [47] The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis
    Kowalec, Kaarina
    Carleton, Bruce
    Tremlett, Helen
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2013, 2 (03) : 183 - 192
  • [48] Multiple sclerosis and pregnancy
    Kanagaraj, Priya
    Evangelou, Nikos
    Kapoor, Dipanwita
    OBSTETRICIAN & GYNAECOLOGIST, 2019, 21 (03) : 177 - 184
  • [49] Overlapping and distinct mechanisms of action of multiple sclerosis therapies
    Graber, J. J.
    McGraw, C. A.
    Kimbrough, D.
    Dhib-Jalbut, S.
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2010, 112 (07) : 583 - 591
  • [50] Pregnancy and Multiple Sclerosis
    Coyle, P. K.
    NEUROLOGIC CLINICS, 2012, 30 (03) : 877 - +
12345